Back to Search
Start Over
Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG)
- Source :
- Cancer chemotherapy and pharmacology. 73(4)
- Publication Year :
- 2014
-
Abstract
- To evaluate the safety and antitumor activity of docetaxel (DOC) and pegylated liposomal doxorubicin (PLD) combination in patients with platinum- and taxane-sensitive ovarian cancer.Twenty-three patients were enrolled. DOC was administered at the dose of 40 mg/m(2) intravenously (i.v.) and PLD at 20 mg/m(2) i.v. on days 1 and 15 in cycles of 28 days. The study was closed prematurely due to slow accrual.Seven (30.4 %) patients achieved objective response (three complete, four partial), while five (21.7 %) others experienced stable disease (overall disease control rate 52.1 %). The median progression-free survival was 4.8 months and the median overall survival 18.8 months. Grade 3-4 neutropenia occurred in two (8.7 %) and one (4.3 %) patients, respectively. Febrile neutropenia occurred in two patients. The most common non-hematological grade 3 toxicity was hand-foot syndrome (13 % of patients). There was no treatment-related death.The combination of pegylated liposomal doxorubicin and docetaxel is a well tolerated and a relatively active regimen in pretreated patients with platinum- and taxane-sensitive advanced ovarian cancer.
- Subjects :
- Oncology
Adult
Cancer Research
medicine.medical_specialty
Paclitaxel
Docetaxel
Neutropenia
Carcinoma, Ovarian Epithelial
Toxicology
Carboplatin
Polyethylene Glycols
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Pharmacology (medical)
Neoplasms, Glandular and Epithelial
Prospective Studies
Aged
Pharmacology
Ovarian Neoplasms
Salvage Therapy
Taxane
business.industry
Middle Aged
medicine.disease
Clinical trial
Regimen
Doxorubicin
Toxicity
Female
Taxoids
Neoplasm Recurrence, Local
Ovarian cancer
business
Febrile neutropenia
medicine.drug
Subjects
Details
- ISSN :
- 14320843
- Volume :
- 73
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Cancer chemotherapy and pharmacology
- Accession number :
- edsair.doi.dedup.....7fd7d65e2d5526f36e3406d012c78101